Toward clinical translation of carbon nanomaterials in anticancer drug delivery: the need for standardisation

• Michał Bartkowski,
• Francesco Calzaferri and
• Silvia Giordani

Beilstein J. Nanotechnol. 2025, 16, 2092–2104, doi:10.3762/bjnano.16.144

• enhancing therapeutic delivery, particularly in areas such as cancer treatment. This perspective highlights critical considerations in the development of CNM-based nanocarriers, spanning from initial design to clinical implementation. Keywords: carbon nanomaterials (CNMs); carbon nanoparticles (CNPs); drug

• -consuming production, and a lack of standardised methods for their characterisation. Nevertheless, growing research into CNM-based nanoformulations continues to address key challenges, underscoring their promise in enhancing therapeutic delivery; particularly in cancer treatment, where the global burden

• treated. Perspective The development of a novel CNM-based drug delivery system for targeted anticancer therapeutic delivery is a complex and multistep process that involves several key milestones (Figure 3), each of which requires distinct expertise in materials science, chemistry, biology, and regulatory

PEGylated lipids in lipid nanoparticle delivery dynamics and therapeutic innovation

• Peiyang Gao

Beilstein J. Nanotechnol. 2025, 16, 1914–1930, doi:10.3762/bjnano.16.133

• PEG; immunogenicity; lipid nanoparticles; PEG alternatives; PEG lipids; therapeutic delivery; Review Introduction Lipid nanoparticles (LNPs) have become a promising platform in modern nanomedicine, especially for delivering genetic payloads such as mRNA and siRNA. These nanoscale particles can

Enhancing the therapeutical potential of metalloantibiotics using nano-based delivery systems

• Alejandro Llamedo,
• Marina Cano,
• Raquel G. Soengas and
• Francisco J. García-Alonso

Beilstein J. Nanotechnol. 2025, 16, 1350–1366, doi:10.3762/bjnano.16.98

• the drug accumulation. Optimization of these parameters helps to maximize efficacy and mitigate toxicity of the payload [39]. Infection sites often present unique microenvironmental features, a factor that nanoparticles exploit to achieve precise therapeutic delivery. For example, polymeric

Synthetic-polymer-assisted antisense oligonucleotide delivery: targeted approaches for precision disease treatment

• Ana Cubillo Alvarez,
• Dylan Maguire and
• Ruairí P. Brannigan

Beilstein J. Nanotechnol. 2025, 16, 435–463, doi:10.3762/bjnano.16.34

• endocytosis enables cellular entry, achieving efficient release and nuclear delivery of ASOs remains a challenge as a consequence of potential sequestration and degradation within endocytic vesicles [79][80]. This issue is prevalent in the majority of therapeutic delivery systems that enter via endocytosis

Development of a mucoadhesive drug delivery system and its interaction with gastric cells

• Ahmet Baki Sahin,
• Serdar Karakurt and
• Deniz Sezlev Bilecen

Beilstein J. Nanotechnol. 2025, 16, 371–384, doi:10.3762/bjnano.16.28

• protein-digesting enzyme pepsin [44]. Despite the challenges, remarkable developments are unfolding. Recently a peptide-based therapeutic delivery system that is absorbed in the stomach was approved by the FDA as oral formulation to be used in type-II diabetic patients [45]. This inspired us to develop

Nanocarriers and macrophage interaction: from a potential hurdle to an alternative therapeutic strategy

• Naths Grazia Sukubo,
• Paolo Bigini and
• Annalisa Morelli

Beilstein J. Nanotechnol. 2025, 16, 97–118, doi:10.3762/bjnano.16.10

• shapes like ellipsoids, discoids, and nanorods with higher aspect ratios are more effectively localized close to blood vessel walls, enhancing their internalization into endothelial cells and potentially improving their therapeutic delivery [1]. After systemic administration, NCs tend to accumulate in

Polymer lipid hybrid nanoparticles for phytochemical delivery: challenges, progress, and future prospects

• Iqra Rahat,
• Pooja Yadav,
• Aditi Singhal,
• Mohammad Fareed,
• Jaganathan Raja Purushothaman,
• Mohammed Aslam,
• Raju Balaji,
• Sonali Patil-Shinde and
• Md. Rizwanullah

Beilstein J. Nanotechnol. 2024, 15, 1473–1497, doi:10.3762/bjnano.15.118

• advantageous for chronic conditions requiring long-term treatment, such as cancer, cardiovascular diseases, and neurodegenerative disorders [22][23]. This review aims to discuss the ability of PLHNPs to improve the therapeutic delivery of phytochemicals for biomedical applications. In this review, we discuss

• improved therapeutic delivery [108]. The developed RVT-PLHNPs were stable for a month and showed a controlled drug release. Biocompatibility and cytotoxicity of RVT-PLHNPs were examined by using Vero cells and MCF-7 cells. The results indicate excellent biocompatibility and a higher cytotoxicity of RVT

Nanocarrier systems loaded with IR780, iron oxide nanoparticles and chlorambucil for cancer theragnostics

• Phuong-Thao Dang-Luong,
• Hong-Phuc Nguyen,
• Loc Le-Tuan,
• Xuan-Thang Cao,
• Vy Tran-Anh and
• Hieu Vu Quang

Beilstein J. Nanotechnol. 2024, 15, 180–189, doi:10.3762/bjnano.15.17

• of these systems to serve as medication and imaging agent carriers for cancer treatment and diagnostics, respectively. Keywords: cancer; chlorambucil; F127-folate; IR780; iron oxide nanoparticles; PLGA; theragnostics; Introduction Theragnostic nanoparticles (NPs) are a diagnostic and therapeutic

• delivery system. The delivery system is comprised of three components: the carrier, the imaging agent, and the therapeutic drug, all of which need clinical approval before being used in humans. Poly(lactic-co-glycolic acid) (PLGA) is an approved biodegradable and biocompatible material for clinical use [1

Self-assembly of amino acids toward functional biomaterials

• Huan Ren,
• Lifang Wu,
• Lina Tan,
• Yanni Bao,
• Yuchen Ma,
• Yong Jin and
• Qianli Zou

Beilstein J. Nanotechnol. 2021, 12, 1140–1150, doi:10.3762/bjnano.12.85

• biomedical science. The nanostructure of amino acids can be a good substitute for therapeutic delivery due to its good biocompatibility, functionalization, and ease of design/synthesis. Self-assembled nanostructures have become smart tools in the biomedical field, as demonstrated by the ability of self

A review on the green and sustainable synthesis of silver nanoparticles and one-dimensional silver nanostructures

• Sina Kaabipour and
• Shohreh Hemmati

Beilstein J. Nanotechnol. 2021, 12, 102–136, doi:10.3762/bjnano.12.9

• groups [263]. Although viral templates have not been investigated as much as other approaches, viral template-mediated Ag nanostructures have been demonstrating promising potential in targeted imaging and therapeutic delivery systems [272]. In addition, they can be used to synthesize 1D Ag nanostructures

Applications of superparamagnetic iron oxide nanoparticles in drug and therapeutic delivery, and biotechnological advancements

• Maria Suciu,
• Corina M. Ionescu,
• Alexandra Ciorita,
• Septimiu C. Tripon,
• Dragos Nica,
• Hani Al-Salami and
• Lucian Barbu-Tudoran

Beilstein J. Nanotechnol. 2020, 11, 1092–1109, doi:10.3762/bjnano.11.94

Enhanced inhibition of influenza virus infection by peptide–noble-metal nanoparticle conjugates

• Zaid K. Alghrair,
• David G. Fernig and
• Bahram Ebrahimi

Beilstein J. Nanotechnol. 2019, 10, 1038–1047, doi:10.3762/bjnano.10.104

• biological activity of the peptide, for example, due to multivalent functionalisation of the nanoparticles. In addition, silver possesses innate antimicrobial activities [25]. Thus, noble-metal nanoparticles are potentially useful as both functional probes for antiviral peptides and as therapeutic delivery